ERCC2 and ovarian cancer: Some studies have suggested that low ERCC2 expression is associated with increased chemotherapeutic sensitivity and thus considered a predictive marker for patients with ovarian cancer receiving combination gemcitabine and cisplatin chemotherapy [13].